The Impact of Infectious Disease on QT Segment

• Sponsor: HaEmek Medical Center, Israel (Other)
• Overall Status: Completed
• CT.gov ID: NCT02960256
• Collaborator: (none)
• Enrollment: 169
• Location: 1
• Actual Duration (Months): 3
• Patients Per Site Per Month: 57.2

Study Details

Study Description

Brief Summary

Sepsis related to the development of cardiac complications. However, the investigators understanding regarding this condition remains incomplete. Possible explanations raised include coronary perfusion decrease, activation of the coagulation system and release of inflammatory mediators, including endotoxins, cytokines and others.

In this study the investigators wanted to examine the impact of any infectious disease, (not necessarily Pneumonia), on the QT interval in patients hospitalized for acute infectious disease.

Condition or Disease	Intervention/Treatment	Phase
Sepsis; Pneumonia; Cardiomyopathy, Secondary	Device: ekocardiogram test

Study Design

• Study Type: Observational
• Actual Enrollment: 169 participants
• Observational Model: Cohort
• Time Perspective: Prospective
• Official Title: The Impact of Infectious Disease on QT Segment
• Actual Study Start Date: Dec 1, 2016
• Actual Primary Completion Date: Mar 1, 2017
• Actual Study Completion Date: Mar 1, 2017

Arms and Interventions

Arm	Intervention/Treatment
Patients admitted to an internal medicine department due to an	Device: ekocardiogram test; ekocardiogram test

Outcome Measures

Primary Outcome Measures

1. Prolongation of the QT [5 days]

   QT will be measured by ECG

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years to 120 Years
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

• Internal ward hospitalized patient, due to illness which its etiology is bacterial, fungal or viral

Exclusion Criteria:

• Can not technically perform reliably ECG (amputated legs, lack of cooperation, etc.)

• Subject with permanent pacemaker

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Haemek Medical Center	Afula		Israel

Sponsors and Collaborators

• HaEmek Medical Center, Israel

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Lee Goldstein, Principal Investigator, HaEmek Medical Center, Israel
• ClinicalTrials.gov Identifier: NCT02960256
• Other Study ID Numbers: 112-16
• First Posted: Nov 9, 2016
• Last Update Posted: Mar 14, 2018
• Last Verified: Mar 1, 2018

• Individual Participant Data (IPD) Sharing Statement: No
• Plan to Share IPD: No
• Additional relevant MeSH terms: Communicable Diseases; Infections; Cardiomyopathies

Study Results

No Results Posted as of Mar 14, 2018